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白花中药前胡 (Peucedanum praeruptrum Dunn) 为伞形科植物白花前胡的
干燥根，具有散风清热，降气化痰的功效，作为止咳化痰平喘药而广泛应用。白
花前胡甲素 (dl-praeruptorin A，Pd-Ia) 为白花前胡根中提取出的一种角型吡喃香
豆素，是一种脂溶性物质。近年来，药理研究表明，Pd-Ia 作为一种钙阻滞剂和
钾通道开放剂，具有保护心肌缺血和局灶性脑缺血急性损伤作用。但是，在我们
前期研究中发现，Pd-Ia 在大鼠体内的半衰期短，主要由 CYP3A 催化、代谢；大
剂量 Pd-Ia 口服给药后，在血液中也很难检测到，可能被胃肠道或肝内的 CYP3A
代谢，首过效应强。 
目的：将难溶性药物 Pd-Ia 制成 O/W 微乳，改善 Pd-Ia 的溶解度，提高药物的稳
定性与载药量。通过绘制伪三元相图和体外经皮渗透实验，筛选出 优处方，并













1. Pd-Ia 在水中溶解度很低 (25 °C，5.57 μg·mL-1)，为脂溶性药物，在 33%乙醇
/生理盐水中的溶解度为 458.43 μg·mL-1，选择 33%乙醇/生理盐水 (v/v) 作为接受
介质，满足漏槽条件。 















(25 °C，17.149 mg·mL-1)。选择 5%油酸做油相，Cremophor RH40/Ethanol (1:2，
g/g) 为混合表面活性剂，混合表面活性剂用量为 40%时，为 优处方。在 10000 
× g 下离心 15 min 后保持澄清，粒径大小约为 50 nm，且分布均 。 优处方载
药量为 5 mg·g-1 时，经皮渗透速率 J 为 11.713 μg·cm-2·h-1，32 h 累积渗透量 Qn 为
353.266 μg·cm-2。 
3. 微乳凝胶的制备及体外经皮渗透吸收的评价：以 1.4% Carbomer 940 凝胶基
质作为水相，按照微乳 优处方，制备 0.84% Pd-Ia 微乳凝胶，经皮渗透速率 J
为 12.671 μg·cm-2·h-1，32h 累积渗透量 Qn 为 316.77 μg·cm-2。 
结论：O/W 微乳增加了 Pd-Ia 的溶解度，经皮渗透速率明显提高。O/W 微乳凝胶





















Qianhu (Peucedanum praeruptorum Dunn) is one of the most popular traditional 
Chinese medicinal plants, and usually used in antitussive, apophlegmatisant, 
antiasthmatic and remedying against angina. dl-Praeruptorin A (Pd-Ia), an 
angular-type pyranocoumarin isolated from Qianhu, has been proved to be a novel 
Ca2+-influx blocker and K+-channel opener. Additionally, Pd-Ia has a neuroprotective 
effect on the myocardial ischemia and the injury in the acute phase of transient focal 
cerebral ischemia.  
It was reported that the elimination half-life (t1/2) of Pd-Ia was approximately 60.87 
min by a single i.v. administration in rats. We also tried to conduct pharmacokinetic 
study of Pd-Ia by oral route in rats. However, the concentration of Pd-Ia in plasma 
was too low to be detected even the oral dose was up to 100 mg/kg.  
Object  To increase the solubility, the stability and penetrating flux of Pd-Ia, the 
O/W microemulsion as potential transdermal drug delivery vehicle was prepared . The 
formulation of microemulsion by preparing the pseudo-tertiary phase diagrams and 
the transdermal experiments were screened, the microemulsion-based gel with 
water-soluble base materials (Carpomer 940) according to the optimal formulation 
was prepared, and the transdermal ability of the various systems was estimated. At the 
same time, we investigated the appearance, size distribution, morphology and stability 
of microemulsion.  
Methods 
1. In this project, the analytical method of high performance liquid chromatogram 
(HPLC) for Pd-Ia was established. The HPLC-UV method was established to 
determine the concentration of Pd-Ia in receptor compartment. Meanwhile the 
apparent oil-water distribution coefficient and the solubility of Pd-Ia were determined, 
and the receptor medium was selected to keep the skin condition. 
2. The preparation of Pd-Ia microemulsion  















The surfactants, co-surfactants and component of ratio were determined through 
preparing the pseudo-tertiary phase diagrams. The optimal formulation of Pd-Ia 
microemulsion was screened by the transdermal permeation experiment in vitro. 
Through the transdermal flux of the different content of Pd-Ia microemulsions, the 
largest drug loading of Pd-Ia microemulsions was determined.  
3. The preparation of Pd-Ia microemulsion-based gel 
The optimal formulation of Pd-Ia microemulsion-based gel was selected by the 
viscosity as index. We investigated initially its physical and chemical properties. The 
microemulsion microemulsion-based gel and control gel of Pd-Ia were evaluated 
through the transdermal experiment in vitro. 
Results 
1. According to the preformulation investigation, Pd-Ia is a lipid-soluble drug with a 
poor water-solubility (25 °C，5.57 μg·mL-1). The solubility of Pd-Ia is 458.43 μg·mL-1 
in 33% Ethanol/saline (v/v). 33% Ethanol/saline was selected to maintain the skin 
condition as the receptor medium in transdermal experiments. 
2. The preparation of Pd-Ia microemulsion and the evaluation of its transdermal 
experiments: The solubility of Pd-Ia was higher in OA. The optimum formulation of 
microemulsion vehicle was composed of 5% OA, 40% the combining of Cremophor 
and Ethanol (1:2, g/g), and 52.5% ultrapure water. The optimizing microemulsion was 
maintained to be clear, and distributed uniformity after centrifuged 15 min at 10000 × 
g. The penetration rate of optimized microemulsion was 11.713 μg·cm-2·h-1, and the 32 
h cumulative permeated amount was 353.266 μg·cm-2. 
3. The microemulsion-based gel was prepared according to the optimum 
formulation of microemulsion, but the ultrapure water of microemulsion was replaced 
by water-soluble gel-base (1.4% carbomer 940 solution) in MBG. The penetration rate 
of optimized microemulsion-based gel was 11.713 μg·cm-2·h-1, and the 32 h 
cumulative permeated amount was 353.266 μg·cm-2. 
Conculsion: The Pd-Ia solubility and penetration rate through preparing O/W 
microemulsions were improved. The O/W microemulsion-based gels were 















microemulsion-based gels may provide a new preparation with high efficiency, low 
toxicity, convenience and stability. 
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第一章  课题背景 
1 
第一章  课题背景 
1.1  白花前胡甲素研究现状 
中药前胡为伞形科植物白花前胡 (Peucedanum praeruptrum Dunn) 或紫花
前胡 (P. decursivum maxim) 的干燥根[1]，具有散风清热，降气化痰的功效，作为
止咳化痰平喘药而广泛应用[2]。但两个基源药材主要化学成分差异大，白花前胡
以角形吡喃香豆素成分为主，已分离出白花前胡甲素 (dl-praeruptorin A)、乙素 







图1.1  白花前胡甲素的结构式 
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